The panellists will explore:
- The evidence required for health economic modelling, with a focus on partitioned survival modelling for oncology
- Challenges posed by immature data or single-arm studies
- How RWD can fill the gap
- What RWD look like in practice
- How RWD and RWE can support the HTA process
- How RWD can be used to generate external control arms
- Using RWD in an HTA submission – the assessor’s perspective
The webinar is free and open to all market access, health economics, and HTA professionals in Pharmaceutical and Medtech companies. We also welcome attendees from healthcare systems. Some colleagues from other organisations may attend at the discretion of the organisers.





